



Rybrevant in India

The CDSCO named-patient coordination pathway — indicative 2026

ONCOLOGY · EGFR/MET BISPECIFIC NSCLC

The clinical situation

Rybrevant (amivantamab) is a fully human EGFR/MET bispecific antibody for NSCLC with EGFR exon 20 insertions (and, in expanded indications, specific EGFR-mutant combination regimens). Manufactured by Janssen. Administration is IV on a weight-based schedule — a split first-dose followed by weekly dosing for four weeks, then every two weeks. Infusion-related reactions are common on cycle 1 and require premedication; skin and nail toxicity management is routine.

The pathway, 5 steps

- 1 Consultation & clinical rationale.** Your oncologist confirms EGFR exon 20 (or combination-indication molecular profile) and documents prior-therapy sequence.
- 2 Molecular-testing confirmation.** NGS report documenting the qualifying EGFR alteration.
- 3 CDSCO personal-use application.** Rationale, patient reference, infusion plan, and chain-of-custody filed.
- 4 US-side sourcing & logistics.** Reserve Meds coordinates product through our US-licensed DSCSA-compliant specialty wholesale partner under cold chain.
- 5 First infusion & ongoing cadence.** The oncology team administers with premedication; weekly loading transitions to every-2-week maintenance.

Indicative economics

Reference US cash-pay range: USD 18,000–23,000 per month at maintenance (weight-based; drug-only reference; Reserve Meds provides a transparent delivered quote at intake). Weekly loading phase carries higher burden.

Indicative first-dose timing

7–14 days from a complete CDSCO application to first infusion, once cohort intake opens. Indicative — not guaranteed.

Reserve Meds's role

Sourcing. US-licensed specialty wholesale partner, DSCSA chain-of-custody. **Documentation.** Regulatory package for your physician and CDSCO review, keyed to the EGFR exon 20 or combination-therapy rationale. **Logistics.** Cold-chain shipment with importer-of-record handling. **Concierge case lead.** Named point of contact for family and oncology team. **We are a coordinator** — not the prescriber, not the dispensing pharmacy. All clinical decisions remain with your treating oncologist.

COMPOSITE EXAMPLE · PRE-LAUNCH WAITLIST

Join the Rybrevant × India first-cohort waitlist. *Our concierge reaches out as we open intake.*

reservemed.com/access-guides/rybrevant-india.html



SCAN TO JOIN

Reserve Meds · US-based concierge for cross-border specialty medicine. We are a coordinator; we are not the prescriber and not the dispensing pharmacy. All clinical decisions remain with the treating physician. Not medical advice.

Reserve Meds is in pre-launch. Service availability is limited to our first cohort; all timelines published are indicative, not guarantees. Composite case examples only.

reservemed.com · hello@reservemed.com · WhatsApp concierge: +1 516 528 3120 · Reviewed 2026-04-23 by Reserve Meds clinical & regulatory team